Archive for the ‘Pressure BioSciences Inc. PBIO’ Category

RedChip Featured Company: Pressure BioSciences, Inc. (PBIO)

Saturday, August 16th, 2008

Pressure BioSciences, Inc. (PBIO) is focused on developing products based on its proprietary pressure cycling technology (PCT) for life-sciences applications. The innovative technology utilizes hydrostatic pressure, which cycles between ambient and ultra-high levels, to rapidly and proficiently disrupt cell membranes/tissues to remove nucleic acids, proteins, and small molecules from plant and animal materials.

The PCT technology has a broad range of possible applications in genomics and proteomics, in addition to drug discovery, pathogen inactivation, food safety, immunodiagnostics, and DNA sequencing. Currently, the PCT System consists of a top-of-the-line instrument and disposable PULSE sample processing tubes. Pressure BioSciences plans to develop other instrumentation and disposables to meet additional needs in life sciences’ laboratories.

The Company’s proprietary technology addresses the number one issue in sample preparation that creates significant bottlenecks in research. Existing technology does not product consistent results, requires multiple steps, and has a high risk of contamination. By utilizing Pressure BioSciences’ PCT technology, researching can achieve much better results in a single-step process.

The CEO and President of Pressure BioSciences, Mr. Richard T. Schumacher, founded the company in 1978 as Boston Biomedica, which later became known as Pressure BioSciences in 2004. He has extensive experience in the medical field, helped build Panacos Pharmaceuticals into a public company valued at more than $200 million, and guided Boston Biomedica from a start-up company to realizing $30 million in sales as Pressure BioSciences.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Dutton Associates Featured Company: Pressure BioSciences, Inc. (PBIO)

Thursday, July 10th, 2008

Pressure BioSciences, Inc. (PBIO) is focused on developing products based on its proprietary pressure cycling technology (PCT) for life-sciences applications. The innovative technology utilizes hydrostatic pressure, which cycles between ambient and ultra-high levels, to rapidly and proficiently disrupt cell membranes/tissues to remove nucleic acids, proteins, and small molecules from plant and animal materials.

The PCT technology has a broad range of possible applications in genomics and proteomics, in addition to drug discovery, pathogen inactivation, food safety, immunodiagnostics, and DNA sequencing. Currently, the PCT System consists of a top-of-the-line instrument and disposable PULSE sample processing tubes. Pressure BioSciences plans to develop other instrumentation and disposables to meet additional needs in life sciences’ laboratories.

The company’s proprietary technology addresses the number-one issue in sample preparation that creates significant bottlenecks in research. Existing technology does not produce consistent results, requires multiple steps, and has a high risk of contamination. By utilizing Pressure BioSciences’ PCT technology, researchers can achieve much better results in a single-step process.

The CEO and president of Pressure BioSciences, Mr. Richard T. Schumacher, founded the company in 1978 as Boston Biomedica, which later became known as Pressure BioSciences in 2004. He has extensive experience in the medical field, helped build Panacos Pharmaceuticals into a public company valued at more than $200 million, and guided Boston Biomedica from a start-up company to realizing $30 million in sales as Pressure BioSciences.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

RedChip Visibility Issues Fourth Quarter 2007 Research Update on Pressure BioSciences, Inc. (PBIO)

Thursday, May 1st, 2008

RedChip Visibility recently issued a fourth quarter 2007 research update on Pressure BioSciences, Inc. (NASDAQ: PBIO), a life sciences company focusing exclusively on the development and commercialization of pressure cycling technology, reinstating their “Speculative Buy” rating and 12-month target price of $10.00 per share.

The report also stated that PBIO reported more than a threefold year-over-year increase in revenues in the fourth quarter of 2007 as a result of the company’s strong commercialization strategy with an expanded sales force and efficient research and development staff. Pressure BioSciences’s pressure cycling technology (PCT) has multiple applications, including genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions (particularly enzymes), immunodiagnostics, protein purification, and food safety.

The recent introductions of two new products, Proteosolve-LRS and ProteoSolve-SB kits, highlight the growing demand and number of demonstrated applications for the PCT technology in specific disease diagnosis and analysis. The report went on to state that the company’s superior technology coupled with the introduction of consumables kits will, in their opinion, accelerate sales in 2008.

Let us hear your thoughts below:

Pressure BioSciences, Inc. (PBIO) Reports 2007 Financial Results and Provides Business Update

Wednesday, March 12th, 2008

Pressure BioSciences, Inc. announced its total revenue for 2007. Revenue for the year totaled $645,870, a significant rise compared 2006’s revenue of $210,289. An increase in sales of PCT products and services was primarily attributed to the increase in revenue.

According to Pressure BioSciences, 20 PCT Systems were installed during 2007, which is more than double the 8 that were installed in 2006. An increase in the number of PULSE Tubes and ProteoSolve-LRS Kits sold also contributed to the substantial increase in revenue. In addition, the Company recorded $246,083 of grant revenue during 2007, while no grant revenue was reported during 2006.

As of the year end of 2007, the Company had cash and cash equivalents of about $5.4 million, slightly higher than the approximate $5.3 million reported for December 31, 2006. Edward H. Myles, Senior Vice President of Finance and CFO stated, “During 2007, we effectively financed the continued development and initial commercialization of PCT with proceeds received from the liquidation of our investment in Panacos Pharmaceuticals common stock, the divestiture of Source Scientific LLC, and the sale of 126,750 shares of our common stock in our private placement completed in November 2007.”

He continued, “Our installation of twenty PCT Systems represents a significant increase compared to the prior year. These installations came in the form of sales, leases, and rental agreements. Furthermore, included in our 2007 revenue was the sale of several of our recently launched Barocycler NEP2320 units, which have a price of approximately one half of the Barocycler NEP3229. Consistent with our strategy, we are working to drive our installed base of PCT Sample Preparation Systems so that we can continue to realize increases in our recurring revenue streams from PULSE Tubes, ProteoSolve-LRS Kits, and extended service contracts.”

Richard T. Schumacher, Founder, President, and CEO of Pressure BioSciences, Inc. added, “We are proud of the accomplishments of 2007 and believe that these accomplishments position us well for success in 2008. On the sales and marketing front, we have completed the hiring of seven experienced, US-based, Regional Sales Directors. Through the efforts of our marketing department, we have increased the number of leads in the US by over 2,000, and we expect that our new Regional Sales Directors will contact many of them during 2008. We also are ahead of schedule in building our international distribution network as we now have distribution agreements with three partners covering France, Switzerland, Belgium, Japan, and Korea.”

“On the research and development side of the business, our accomplishments are numerous: in Engineering R&D, we drove the Barocycler NEP2320 from concept to prototype to product launch in less than a year, and in Applications R&D, we drove our ProteoSolve-LRS Kit from discovery to patent filing to scientific meeting presentation to product launch in less than eight months. In addition, in December 2007, we were awarded the prestigious Frost and Sullivan Innovation Research Award for the development of ProteoSolve-LRS,” Mr. Schumacher continued.

In conclusion, Mr. Schumacher stated, “We look to 2008 as the year that all of the ingredients for success may come together. We have revolutionary technology, a newly hired but experienced sales force, product in inventory, and a potential universe of approximately 390,000 scientists worldwide who might benefit from the advantages of the PCT Sample Preparation System. I am very proud of the progress that we’ve made in the three short years since we became Pressure BioSciences, I would like to compliment all of our employees for their hard work and dedication to date, and I would like to thank all of our shareholders for their past and continued support.”

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure BioSciences Inc. (PBIO) Hires Matthew Potter to Join Management Team as the Vice President of Sales

Tuesday, March 11th, 2008

Today Pressure BioSciences Incorporated announced that it has added a new member to its senior executive management team; Vice President of Sales. Matthew B. Potter will now oversee Pressure Biosciences’ seven US-based, regional sales directors and will be responsible for driving the Company’s commercialization of their novel and patented pressure cycling technology (PCT) product line. Matthew Potter brings just short of twenty years of sales and management experience in both the pharmaceutical and biotechnology fields.

Potter has been a Sales Manager at Pharmacia Biotech; National Sales Director at Visible Genetics; Director, Sales and Marketing at MicroCal, LLC; National Sales Manager, Key Accounts — Pharma at Qiagen, Inc; and Vice President of Sales and Marketing at Abcam, Inc. Before his transition into sales, Mr. Potter was a researcher at the Worcester Foundation for Experimental Biology. Mr. Potter holds a BA in Biology from Clark University and an MBA from Assumption College, both located in Worcester, MA.

Potter said, “In over 19 years of selling products into the research marketplace for the analysis of nucleic acids, proteins, and small molecules, one issue — how to achieve high quality extraction of bio- molecules prior to analysis — nearly always rose to the top. This was always a key issue, and to that end, I believe strongly that the PCT Sample Preparation System answers many of the sample preparation problems that researchers encounter, and offers unique advantages to customers looking to extract DNA, RNA, proteins, and small molecules from a wide variety of biological samples. PBI has a dedicated and talented group of people throughout the organization, and I look forward to working with them — and in particular our newly hired field sales organization — to drive this technology into the marketplace.”

The addition of Potter was meant to give Dr. Nathan Lawrence, who previously led sales and marketing, an opportunity to focus solely on marketing both domestically and abroad. PBI’s Founder, President, and CEO, Richard T. Schumacher, said, “This new focus for Dr. Lawrence will allow us to align our sales and marketing efforts in a manner that supports our Company’s transition to a fully commercial operation in 2008.”

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure BioSciences, Inc. (PBIO) Announces Relocation to New Corporate Offices

Monday, March 10th, 2008

Pressure BioSciences announced today that they have moved their offices in order to accommodate the transition from an early-stage research and development company to a fully commercial operation. The Company’s new address was provided as follows: 14 Norfolk Avenue in South Easton, Massachusetts 02375. While the corporate address was relocated, the Company’s primary research and development facility will continue to be located at 6 Gill Street in Woburn, MA.

“We now have approximately 5,500 square feet, with sufficient office, conference, engineering lab, and storage space to allow us to better develop our infrastructure to support our PCT product commercialization. In addition, the 18 month lease, with equal term extension, gives us the financial flexibility we require as we continue to grow our business and carefully manage our financial resources,” stated Richard T. Schumacher, Pressure BioSciences’ Founder, President, and CEO.

Pressure BioSciences is focused on developing Pressure Cycling Technology (PCT) which uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions. The technology has broad applications in the life sciences field including: genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions, immunodiagnostics, and protein purification. The Company holds 13 US and 6 foreign patents that cover various PCT applications.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences, Inc. (PBIO) – Equipped with Product Line to Fight Disease

Thursday, March 6th, 2008

Founded in 1978, Pressure Biosciences (NASDAQ: PBIO) began significant operations in 1986 and went public 10 years later in 1996, under its former name, Boston Biomedica, Inc. Today the company holds 13 U.S. patents and four foreign patents for applications of its Pressure Cycling Technology (PCT), used in the healthcare field for genomics, proteomics and nucleic acid testing with the ability to rupture cells to release significantly more proteins in fatty tissue.

The company’s PCT Sample Preparation System (PCT SPS) allows for the safe, rapid and reproducible extraction of DNA, RNA, small molecules and proteins. PCT SPS combines the company’s Barocycler NEP3229 with its PULSE Tubes to process and extract up to three samples of animal, plant or microbial samples which can be processed and extracted within minutes. The system’s computer-controlled protocols ensure consistent sample extraction.

Pressure Bioscience’s technology is applicable to various life sciences areas, drawing customers from academic laboratories, government agencies and biotechnology sectors.

The products are used to further the study of various diseases such as heart disease, strokes, cancer and diabetes. The company’s product line includes its latest product, the ProteoSolve Kit, assisting in the research of obesity; the Barocycler NEP2320, Barocycler NEP3229; and its aforementioned PULSE Tubes.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences Inc. (PBIO) Technology Presented in American College of Gastroenterology Study

Monday, March 3rd, 2008

Recently the company’s’ cutting edge Pressure Cycling Technology was featured in a Study conducted by the American College of Gastroenterology. The results were presented at the society’s annual Scientific Meeting.

Scientists conducted the study to identify certain Biomarkers in Colon Cancer. The company’s Pressure Cycling Technology or (PCT) captures the most complete extraction of tissue proteins. This enables exquisite sample preparation for use in research.

As Colon Cancer is a leading cause of death in the United States, the study sought to identify certain Biomarkers that could identify the disease at its earliest stages. Studies have shown that identifying the Disease Biomarkers at the earliest stages allows for the highest cure success rates. The company’s PCT technology is the key to identifying these as it extracts the proteins used in research.

Dr. M. Momeni of the Brooklyn Hospital Center presented the results of the study. Several Scientists compiled data at the Brooklyn Hospital Center and New York University School of Medicine to be presented at the Annual Meeting.

Vice President of R&D for Pressure Biosciences Inc. stated his feelings on the results of the study, “The data presented by Dr. Momeni and her colleagues indicate that an apparent tumor signature protein (hCG1787564) extracted from colon tumor tissue by PCT might be a biomarker that could be of benefit to surgeons treating colon cancer patients. It is gratifying that PCT is beginning to be used by independent scientists in the preparation of their samples for important scientific studies, such as in the case of colon cancer research.”

Pressure Bioscience is an early stage company that focuses on creating and developing innovative technologies, specifically the company’s patented technology, Pressure Cycling, for sample preparation. Its Barocycler NEP3229 uses this technology to process multiple samples within minutes with the ability to customize depending on the sample type needed. They hold 13 US and 4 foreign patents covering many applications of their technology in the life sciences field.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Expanded Sales Force Earns Pressure BioSciences, Inc. (PBIO) a “Speculative Strong Buy” Rating and Increased Sales

Wednesday, February 27th, 2008

Dutton Associates recently rated Pressure BioSciences, Inc. (NASDAQ: PBIO) as a “Speculative Strong Buy,” pricing the 12-month target at $10 per share. The research report commends the company on its “unique and superior technology” applicable to a variety of areas in the life-sciences field.

As Pressure BioSciences utilizes its expanded sales force, Dutton said it expects sales to increase in the upcoming quarters of 2008. The company’s Commercialization Plan called for the addition of seven full-time sales directors to help the company spread its regional coverage.

The sales force is responsible for the marketing of the Barocylcer NEP3229, the Barocycler NEP2320, PULSE Tubes (used in conjunction with the Barocyclers), and the company’s most recent product, ProteoSolve.

The company’s base technology is Pressure Cycling Technology (PCT), a sample preparation system that uses rapid, repeated, alternating cycles of hydrostatic pressure for cell component extraction. The company’s technology and instruments are used to further studies against obesity and related diseases through the research and development of sample preparation for genomic, proteomic and small molecule studies.

In November 2007, Pressure BioSciences announced an increase in its sales of the Barocycler NEP 3229 and an order from its manufacturer for 20 additional units. It also announced the installation of four Barocycler NEP2320 instruments, and an order for 40 more units from the company’s manufacturer.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

RedChip Covering of Pressure BioSciences Inc. (PBIO) Now Available for Online Viewing

Tuesday, February 19th, 2008

Pressure BioSciences Inc.’s (Nasdaq:PBIO) February 2008 IPTV interview with RedChip Visibility is now available at http://www.visualwebcaster.com/Redchipfeb2008/. PressureBiosciences is one of 32 small-cap companies presented at RedChip Companies’ Small-Cap Investor Conference in Scottsdale, Ariz, earlier this month.

RedChip, an international small-cap research and financial public relations firm, covered companies in a wide range of sectors, such as technology, energy, consumer goods, healthcare, commodities, renewable energy and more.

The RedChip mission is to expose small-cap companies that meet specific criteria (effective management, mass appeal, growing sales, improving margins and profitability or near-term profitability) before they hit mainstream Wall Street. PressureBiosciences made the cut; the interview highlights the company’s products, business strategy, management and more.

PressureBiosciences is a life sciences company focused on the research, development, and commercialization of sample preparation systems. The company’s proprietary pressure cycling technology (PCT) uses cycles of hydrostatic pressure between ambient and ultra-high levels to control bio-molecular interactions for genomic, poteomic and small molecule studies. PressureBiosciences holds 13 U.S. and 5 foreign patents covering multiple applications of PCT in the life sciences field to shed light on diseases.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences, Inc. (PBIO) Rolls Out New ProteoSolveLRS Kit to Battle Obesity

Friday, February 15th, 2008

According to the most recent National Health and Nutrition Examination survey, roughly two-thirds of the adults in the United States are overweight, slowly closing the gap between themselves and the one-third of Americans considered obese. Analyzing the protein from lipid-rich tissues helps researchers understand the disease that kills about 300,000 people each year in the U.S. Additionally, obesity is linked to heart disease, stroke, cancer and diabetes.

PressureBiosciences, Inc. (NASDAQ: PBIO) developed Pressure Cycling Technology (PCT) which uses cycles of hydrostatic pressure, as well as other patented technology applicable in the life sciences field for genomic and proteomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics and protein purification.

The company recently rolled out the new detergent-free ProteoSolveLRS Kit, to be used in collaboration with PCT to extract proteins from lipid-rich samples. The ProteoSolveLRS lack of detergents gives it an upper hand over traditional methods that can produce disappointing results, thereby interfering with analytical methods.

According to Pressure Biosciences, when ProteoSolveLRS is used with PCT, it is possible to divide the lipid and protein components within a sample, allowing for higher protein recovery and reproducibility compared to traditional detergent-based methods. It also allows researchers to identify novel proteins, analyze lipid composition and discover biomarkers, all important to the fight against obesity.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences, Inc. (PBIO) Up Almost 8% after Increased interest from Investors Who Attended the Red Chip Conference

Tuesday, February 12th, 2008

At the Red Chip conference in Scottsdale, Arizona, Pressure Biosciences Inc. CEO Richard Schumacher spoke to investors along with 30 other companies. He discussed the unique opportunity that his company has. Mr. Schumacher started the company in his garage when it was then named ‘Biomedica.’ The company recently changed its name to Pressure Biosciences and focuses exclusively on Pressure Testing sciences. They also went from trading on the OTC exchange to the NASDAQ.

In the conference, he stated that Pressure technology, patented by them, has a number of uses including Inactivation of Pathogens, Food Safety, Immunologistics, Protein Purification, Control of Chemical Reactions and Genomic/Proteometic Sample Preparation.

The market for its initial products is huge. Mr. Schumacher stated that there are over 390,000 researchers in 80,000 labs. The company has set a goal to capture 5% of this market share or about 4000 instruments in the next 5 years. They intend to do this through their recently enlarged sales staff that is experienced in the medical product sales field.

He also commented on the strong financial position the company is in. The current Book Value is $3.78 and the company trades at $5.64 a share. In two years, the company has gone from Idea to commercialization. They also have a number of well-publicized research breakthroughs giving their product excellent exposure. They offer investors an exceptional opportunity to get into a burgeoning Medical products industry with a breakthrough technology.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences Inc. (PBIO) Holds Key to Future Biotechnology Business

Friday, February 8th, 2008

There are five compelling reasons to invest in this stock.

1. The company has used funds to develop a technology of path-breaking importance in all fields of biotechnology. Every laboratory involved in this sector needs to be able to break and reassemble genetic strands rapidly. This company achieves this through a portable device that works simply on hydrostatics.
2. European Union regulators have approved of the device. The management has also secured international certification that their product meets safety standards. Investors can look forward to this Massachusetts based business earning in Euros. The National Institutes of Health have funded research by the company, so approval by US regulators could be imminent as well.
3. The management has earned a Gross Margin of over 78% over the last four quarters, and sales during the last quarter are 50% higher than the comparable period a year ago: it is clear that highly profitable and rapid business growth hide beneath the current stock value.
4. The management has built a wide and deep technical moat around their extraordinary product. They supply a meter to measure rapid changes in pressure, the most important consumables required for laboratory work using their device, and a comprehensive maintenance contract for customers that includes real-time telephone support.

Ask every biotechnologist you know, and you will find consensus that rapid pressure cycling holds the key to bringing new discoveries from genetics and biochemistry to market. There are no guarantees in stock investment, but it does seem to be an incredible opportunity for the stock market to have closed on February 05 2008 with this security quoted at less than $5 a unit!

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

RedChip Upgrades Pressure Biosciences (PBIO.OB) Price Target to $10 Per Share

Friday, February 1st, 2008

For the quarter, ending September 30, 2007, Pressure Biosciences saw revenue grow 50% year over year. This was due mostly to increased sales of PCT instruments. Revenue ended the quarter at $138,000. The Company has been spending considerably on marketing and commercialization of its PCT devices and it should begin to pay off heavily FY2008.

The analyst who completed the report stated, “We maintain our Speculative Buy rating on PBIO stock and raise our 12-month price target to $10 per share from our earlier target of $7 given the Company’s superior technology and our belief that sales will accelerate in FY 2008. We continue to believe that PBIO’s current market price of $4.71 and a book value of $3.29 per share do not adequately reflect the inherent value of the Company.”

“As the number of unit sales continues to grow and the potential applications expand, we believe the market will begin to recognize the profit potential inherent in the Company. When looking at the comps for companies in the space of providing diagnostic tools and supplies, we think our price target is reasonable based on 6.35x P/S multiple our estimate of FY 2008 per share revenue of $1.58,” the analyst continued.

Their products continue to show promise with research scientists and are being showcased at many medical conferences. This publicity along with their strong sales growth makes the $10 price target very reasonable.

Pressure Bioscience is early stage company that focuses on creating and developing innovative technologies, specifically the company has patented Pressure Cycling technology for sample preparation. Its Barocycler NEP3229 uses this technology to process multiple samples within minutes with the ability to customize depending on the sample type needed. They hold 13 US and 4 foreign patents covering many applications of their technology in the life sciences field.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure BioSciences, Inc.’s (PBIO) Technology Trumps Standard Bone DNA Extraction Methods

Wednesday, January 30th, 2008

Using its new, patented technique called Pressure Cycling Technology (PCT), Pressure BioSciences, Inc. (NASDAQ: PBIO) provides a safer, easier and more efficient method for DNA extraction from bone fragments than alternative methods.

Usual methods for the extraction of DNA require pulverization because of the hardness of the bone. It is a time-consuming, open process that carries with it the risk of cross-contamination because the equipment is re-used for each procedure. Additionally, some methods use harsh chemicals, chaotropic agents and silica beads for decalcification.

Pressure BioSciences’ technology eliminates the need for pulverization and harsh chemicals normally required, strengthening its appeal in the healthcare industry. The secret is in PCT which uses alternating cycles of high and low pressures to induce cell lysis, or the “death” of a cell for analysis.

The extracted tissues are placed in PULSE Tubes, undergoing alternating pressure cycles in a device called the Barocycler. The Barocycler is temperature controlled, reducing the risk for exposure or cross contamination.

According to a recent study released by Pressure BioSciences, PCT is essential to obtain DNA from bone if pulverization is not conducted. The data also shows that more DNA is released with PCT than with decalcification without PCT. The system allows forensic scientists to extract DNA in two to four hours, whereas standard methods often take 24 or more hours to complete.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences Inc. (PBIO.OB) Intends to Continue Adding Additional Research and Development Projects as well as Personnel to Expand Product Substantiation

Monday, January 28th, 2008

In an effort to commercialize its products, the company is adding research scientists. They believe that investment in these additional personnel will be beneficial to the implementation of its commercialization plan in two key ways. First, through the publication of uses for current products, and secondly through further inventions that rely on the company’s PCT™ technology. This will ultimately expand the scope of its current products and projects enhancing the company’s strategic position.

A recent study conducted noted that the company’s PCT™ technology helped identify potential colon Biomarkers. Annual Scientific Meeting of the American College of Gastroenterology (ACG) presented the study. Identification of Biomarkers enables doctors to identify the disease earlier and have a higher treatment success rate.

In a related story, the company also received the 2007 North American Frost and Sullivan Award for Technology Innovation, given to companies that have demonstrated excellence in new products and technologies within their industry. The award is for the company’s “development of a method for the detergent-free extraction of proteins from lipid-rich tissues.” PCT™ technology, along with the ProteoSolveLRS kit, resulted in a higher retention of proteins and faster process that is much easier to reproduce.

The company is showing internal as well as external validation of its technology. In addition, it continues to show many other uses for Pressure Cycling Technology. This greatly enhances the attractiveness of the technology and company as it strengthens its strategic position within the marketplace and commercializes its technologies.

Pressure Bioscience is early stage company that focuses on creating and developing innovative technologies, specifically the company has patented Pressure Cycling technology for sample preparation. Its Barocycler NEP3229 uses this technology to process multiple samples within minutes with the ability to customize depending on the sample type needed. They hold 13 US and 4 foreign patents covering many applications of their technology in the life sciences field.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences, Inc. (PBIO.OB) Quarter Highlights, Outlook and Sources of Income

Monday, January 21st, 2008

A number of analysts have issued a strong buy on Pressure Bio-Sciences citing that investors will soon realize the value of the company’s technologies. They have set 12-month price targets significantly higher than the current trading price offering investors the opportunity to profit from this company’s innovative products that could revolutionize the medical world, where it has been well received already.

With its Sales force now in position, they are poised to ramp up demand for their technologies. The company’s main product is its line of Barocycler Instruments. They also receive generous revenue streams from the accompanying Pulse Tubes and ProteoSolve (LRS) kits. Service contacts can be purchased for 10% off the purchase price paid yearly giving another revenue stream. In addition to this they have a number of leasing agreements for the Barocycler and lease revenue is recognized monthly. Another small revenue stream is the company’s Small Business Innovation Research Grant money totaling $31,000 last quarter.

Sales for its products have been steadily increasing as the last quarter recognized $138,052 in revenue for three months, the same period last year showed $92,211. This shows a 49% increase year over year, a testament to the increased Sales coverage and the commercialization of its products. COG is just 40% of most of the products sold and the company seeks to further lower COG through a number of component reengineering initiatives. Cash and Equivalents stands at 6 million ending quarter 3 which the company believes to be enough to support sales and operations through year 2008.

As the larger sales force begins to saturate the market with their marketing campaigns, it is expected that sales will see large growth percentages. The leases are also expected to continue to be a large part of the revenue stream as well as accompanying non-durable products.

This company offers investors the chance to see a prospective 65% gain in share value. As long as the company executes its commercialization plan and its Sales force continues to grow, the 12-month price target of $10 is highly possible and could be even higher depending on how substantial its profits are.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences, Inc. (PBIO) Guided by Seasoned Management Team

Wednesday, January 16th, 2008

Founded in 1978, Pressure Biosciences (NASDAQ: PBIO) began significant operations in 1986 and went public 10 years later in 1996, under its former name, Boston Biomedica, Inc. Today the company holds 13 U.S. patents and four foreign patents for applications of its Pressure Cycling Technology (PCT), used in the healthcare field for genomics (the study of an organism’s hereditary information encoded in its DNA), proteomics (study of structures and functions of proteins) and nucleic acid testing with the ability to rupture cells to release significantly more proteins in fatty tissues.

Four members comprise Biosciences management team – each bringing with him valuable experience to the laboratory. Richard T. Schumacher, founder of the company, has served as director since 1978. Among other accomplishments and jobs, Schumacher worked as the director of Infections Disease Services for Clinical Sciences Laboratory for two years; served as chairman of the board of Boston Biomedica for nine years; and was employed by the Center for Blood Research.

Edward H. Myles first joined Pressure Biosciences as vice president of finance and CFO in 2006, and is now senior vice president of finance and CFO. He has worked as a controller for EMD Pharmaceuticals, an affiliate of Merck; worked in the healthcare investment banking group of SG Cowen Securities; and was corporate controller of Boston Biomedica, among other positions.

Dr. Nathan P. Lawrence, Ph.D. served as director of Research and Development until his promotion to vice president of Marketing and Business Development in 2006. Dr. Lawrence is responsible for the development of protocols based on PCT, and for the development of nucleic acid-based diagnostic assays. He has held several positions in Research and Development, and Manufacturing at Becton Dickinson and Gene Trak Systems.

Dr. Alexander Lazarev, Ph.D. joined Pressure Biosciences in 2006 as director of Research and Development, and advanced to vice president of Research and Development last year. He has worked at the Barnett Institute of Chemical and Biological Analysis at Northeastern University; director of New Technology Development at Proteome Systems, Inc.; and held several senior research positions at Genomic Solutions, Inc. and PhytoChem Technologies, Inc.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences (PBIO.OB) Technologies Help Identify Biomarkers for Breast and Colon Cancers

Tuesday, January 15th, 2008

Recently Dr. Paul Pevsner of the New York University of Medicine presented four posters at a LC –MS course held at Cambridge University England. During his presentation Dr. Pevsner stated that the company’s newest innovative product (ProteoSolve LRS) was instrumental in the discovery of certain Bio-Markers in Breast and Colon cancer that could signal the disease. This patented technology allows for detergent free extraction of the lipids giving a much more homogeneous sample.

Dr. Pevsner stated the following regarding Pressure Biseciences products, “The combination of PCT and ProteoSolveLRS is particularly suited for the study of the small, often nano-quantities of samples that are usually available for proteomic studies. The combination of this method with mass spectrometry instrumentation may become a method of choice for bio-molecular identification, not just in cancer, but in neurological and coronary diseases as well.”

This is excellent news for the company in its initial growth stages as it could open the door for many new disease discoveries as well as cures. Pressure Biosciences products allow for advanced sample preparation that provides Researchers with the purest samples with which to conduct their experiments. New capabilities and potential sample preparation prospects created by the company’s technologies give way to new innovative opportunities in drug discovery, diagnostics, and biotechnology.

Pressure Bioscience is early stage company that is focused on creating and developing innovative technologies. Its Barocycler NEP3229 uses this technology to process multiple samples within minutes with the ability to customize depending on the sample type needed. They hold 13 US and 4 foreign patents covering many applications of their technology in the life sciences field.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences (PBIO) Climbs Up the Chart on Recognition

Thursday, January 10th, 2008

Shares of Pressure Biosciences (NASDAQ: PBIO) are on the rise this afternoon, up nearly 8% in to $4.90. Pressure Biosciences is an early-stage company focused on the development of novel, enabling technology called Pressure Cycling Technology (PCT).

The company’s various products are gaining recognition in the healthcare sector for its diagnostic equipment such as its newest product, the ProteoSolve Kit, and the Barocycler NEP2320, the Barocycler NEP 3229 and PULSE Tubes, as well as 13 U.S. patents and four foreign patents that cover a various applications of PCT.

Each of these products are designed for the life sciences field for further study in genomics and pretoeomic sample preparation, pathogen inactivation, control of enzymes, immunodiagnostics and protein purification.

Pressure Biosciences recently received a Strong Speculative Buy Rating by Dutton Associates, and was spotlighted by scientists at the New York University (NYU) School of Medicine. The university announced that their use of the company’s patent-pending ProteoSolve LRS was largely responsible for the identification of potential biomarkers in breast and colon cancer tissue.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences Inc.’s (PBIO.OB) Technology Noted in Discovery of Potential Biomarkers in Certain Types of Cancers

Tuesday, January 8th, 2008

Scientists at New York University stated that the (ProtoSolve-LRS) was largely responsible for the identification of Biomarkers in Breast and Colon tissue. This machine is the company’s award winning patented technology that uses detergent free extraction of proteins from lipids and other tissues. The research’s results were shown over 2 days at the LC-MS Course symposium at Robison College in Cambridge England.

The company believes that use of its revolutionary technology allows for a better understanding of many disease states including cancer. This is because of the Homogeneity allowed by the companies Pressure Cycling Technology in sample preparation, and use of the patented ProtoSolve-LRS method of protein extraction. Giving researchers what they need to discover potential Biomarkers in many diseases.

Lead research scientists Dr. Paul Pevsner is quoted saying, “Our studies showed that the combination of cycled high pressure (PCT) with the ProteoSolve-LRS kit, used in conjunction with other instrumentation in our laboratory, allowed us to identify potential biomarkers of breast and colon cancer. This is a significant finding, since these potential biomarkers may prove to be important indicators of disease detection and progression. It is possible that these findings may alter the current paradigm of histopathology tissue diagnosis for tumors. In the future, examination of biopsy tissue may require not only histopathology, but also mass spectrometry for complete diagnosis.”

“The combination of PCT and ProteoSolve-LRS is particularly suited for the study of the small, often nano-quantities of samples that are usually available for proteomic studies. The combination of this method with mass spectrometry instrumentation may become a method of choice for bio-molecular identification, not just in cancer, but in neurological and coronary diseases as well,” he added.

Pressure Bioscience is early stage company that is focused on creating and developing innovative technologies specifically the company’s patented technology Pressure Cycling for sample preparation. Its Barocycler NEP3229 uses this technology to process multiple samples within minutes with the ability to customize depending on the sample type needed. They hold 13 US and 4 foreign patents covering many applications of their technology in the life sciences field.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure BioSciences, Inc. (PBIO) to be a Featured Company at the 2008 RedChip Conference

Tuesday, January 8th, 2008

RedChip announced today that Pressure BioSciences, along with more than thirty other companies, will be presenting at this year’s RedChip Small-Cap Investor Conference at the Four Seasons Resort in Scottsdale, Arizona on Feb. 7, 2008 from 8 a.m. to 5 p.m.

The RedChip conference will host expo-style exhibitions, networking events, and financial presentations by small-cap companies representing a range of varying sectors. The conference is completely free for pre-qualified investors, but preregistration is required. Those who are pre-qualified will have the opportunity to attend a free cocktail reception and dinner the day before from 6 p.m. to 8:30 p.m.

The following list of companies are scheduled to present: Pressure BioSciences Inc. (Nasdaq:PBIO), GeoPharma Inc. (Nasdaq:GORX), Worldwide Manufacturing USA Inc. (OTCBB:WWMU), Alternative Construction Technologies Inc. (OTCBB:ACCY), Carbon Sciences Inc. (OTCBB:CABN), Duska Therapeutics Inc. (OTCBB:DSKA), Newtek Business Services Inc. (Nasdaq:NEWT), QPC Lasers Inc. (OTCBB:QPCI), Sharps Compliance Corp. (OTCBB:SCOM), ZAGG Inc. (OTCBB:ZAGG), BioSolar Inc. (OTCBB:BSRC) and more.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences Inc. (PBIO.OB) Offers Pressure Cycling Technology for a Number of Sample Preparations

Monday, January 7th, 2008

Biological samples comprised of difficult to solubilize structural elements can only be solibulized with fully dissolved analytes, destroying the homogeneity of the samples. These processes are also difficult and time consuming. A new approach however has been developed by Pressure Biosciences Inc. that utilizes alternating levels of Hydrostatic pressure resulting in better preserved Bio samples.

The process they have developed is a considerable advancement over other methods of sample preparation. Barocycler NEP3229 was developed to generate alternating levels of hydrostatic pressure. It allows up to 3 samples to be processed simultaneously in minutes. Extraction parameters can be optimized to the specific sample types and can be conducted in a variety of organic solvents.

Some common challenges of sample preparation include: Rigid cell walls, High Protein and Lipid counts, Mineralization, Digestive enzymes, and complex matrices. All of these can effectively be prepared by the company’s device.

In order for Molecular analysis to be done, the samples must be carefully prepared. The system created by Pressure Biosciences is a great advancement in the initial sample preparation for genomics, proteomics, and purification of biomolecules from cells and tissues. The technology also offers many advantages including: safety, reproducibility, convenience, and above all precise control over the process. New capabilities and potential sample preparation prospects created by the technology give way to new innovative opportunities in drug discovery, diagnostics, and biotechnology.

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure BioSciences, Inc. (PBIO) Shares Rebound Over 7%

Thursday, December 27th, 2007

After an inexplicable sell off, PBIO shares rebounded strong. The falling share price has been attributed by many to have been caused by confusion linking Pressure BioSciences, Inc. and Panacos Pharmaceuticals Inc. which neared its 52 week low after disappointing results. Previously Pressure BioSciences had a position in Panacos Pharmaceuticals, but sold off all its interest over six months ago.

The Company has attracted the attention of several analysts and has been awarded 12-month price targets as high as $10 – a near double from the current price. The most recent report published by Dutton Associates on December 18 detailed that shares will begin reflecting the substantial profits that are believed to be generated in 2010.

The projected sales of the Company’s flagship Barocylcer products are estimated to be a total of 24 for 2007, 218 for 2008, 568 for 2009, 1,108 for 2010, and over 1900 for 2011. Dutton Associates estimated that 2010 earnings will total $5.28 million resulting in Earnings Per Share of approximately $1.51 on a 3.49 million fully diluted share base.

In conclusion of their report, the firm stated, “We believe that as the coming 12-month period progresses, Pressure BioSciences will begin to demonstrate its ability to place a rapidly-increasing number of Barocyclers, and that the potential for substantial profits beginning in 2010 will begin to be recognized in these shares.”

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board

Pressure Biosciences, Inc. (PBIO) Posts Recognized Revenue Increases

Friday, December 21st, 2007

Pressure Biosciences (NASDAQ: PBIO) recently announced its September 2007 quarter highlights for the period ended September 30, 2007. The company posted revenue of $138,052, as compared to $92,211 for the same period in 2006. Revenue from the sale of the company’s Pressure Cycling Technology (PCT) sample preparation products and services was $106,787; up from $92,211 from the same period last year.

The increase in revenue is attributed to increased installations of PCTs, which rose to eight installations in the 2007 quarter, as compared to three for the same period of 2006. The company also sold two Barocycler NEP3229s, four Barocycler NEP2320s, rented out two Barocycler NEP3229s, as well as increased the number of PULSE Tubes sold.

Pressure Biosciences also reduced the overall production cost of the NEP3229 through reengineering efforts, while increasing its research and development staff and scientific projects within the company’s laboratories. Sales are expected to increase with the addition of the sales associates.

As of September 30, 2007, Pressure Biosciences had cash on hand and cash equivalents totaling approximately $6.0 million, as compared to $5.3 million on December 31, 2006. According to the statement, the company’s current funds are sufficient to support its growth objectives through the end of 2008.

The company was recently rated a “Strong Speculative Buy” by Dutton Associates due to its “unique and superior technology for the preparation of biological laboratory samples and is in the early stages of commercialization of its product platform.”

Let us hear your thoughts: Pressure BioSciences, Inc. Message Board